HN-2301

N/A

Report date: 2026/05/12 09:17:36

Base Information

Drug NameHN-2301
Drug Alias NameHN2301HN-2301
ClassificationCell and gene therapy > Gene therapy > LNPCell and gene therapy > Gene therapy > mRNACell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > In vivo CAR-T therapy +[4] 
Mechanisms of ActionB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsScleroderma, SystemicLupus Erythematosus, SystemicGraves Disease +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShenzhen MagicRNA Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Zhongshan HospitalShenzhen MagicRNA Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsScleroderma, SystemicLupus Erythematosus, SystemicGraves Disease +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A